In the Indian states of Bihar and Uttar Pradesh, flooding caused by heavy monsoons has put patients with leprosy at severe risk, depriving them of access to urgently needed treatment, according to an article published in *The Herald* on October 3. Although we are used to hearing about the catastrophic consequences of natural disasters, are we aware that leprosy is still a global health issue? Several organisations have suggested this is the case, including WHO, through their Global Leprosy Strategy 2016--2020, *Accelerating towards a leprosy-free world*, launched in 2016.

Leprosy, or Hansen\'s disease, is a communicable infectious disease caused by *Mycobacterium leprae* that affects skin, respiratory tract, eyes, and nerves. The infection progresses slowly, with an incubation period of years. The nerve damage caused by the infection is irreversible and clinical manifestations of secondary infections can result in tissue loss, blindness, and finger and toe deformities. Leprosy can be cured thanks to a multidrug therapy developed in the 1980s, and its introduction in the early 1990s reduced the diffusion of the disease worldwide by 99%, according to a 2017 report from WHO\'s Global Leprosy programme.

The advent of the cure and the general reduction in leprosy burden has caused a rise in the misconception that leprosy is no longer a global health threat, and the commonly held belief that it is an old-age biblical disease---something now only seen in movies such as Ben Hur.

However, according to a WHO report released in September 2019, 208 619 new cases---including more than 16 000 children---from 127 countries worldwide were registered in 2018. Leprosy is primarily affecting those living in poverty and, according to the report, India, Indonesia, and Brazil account for 79•6% of new cases globally. Of note, a small increase in new cases was detected in the Eastern Mediterranean Region, European Region, and in the Americas Region. Clearly, leprosy is not yet eliminated and, even if rare, its sporadic presence is also reported in industrialised countries.

A study by Balestrino and colleagues from the University of Genoa (Italy), published in July 2019, in *Neurological Science*, reported a retrospective case of 21 patients with leprosy neuropathy from 2009 to 2019, in need of surgical treatment in a single centre in Italy. In October 2019, in *PloS Negl Trop Dis*, McCormick and colleagues from the Emory University Rollins School of Public Health Atlanta (Emory University, GA, USA) published epidemiological data describing an increase in leprosy cases in Georgia. Furthermore, a retrospective study published in March 2019, in *Mayo Clin Proc*, by Bezalel and colleagues from the Mayo Clinic, described nine patients infected in a clinic in Rochester (MN, USA) in a period spanning 1994 to 2017. Although causes for disease contraction might vary, including contact with armadillos, all three of these studies warned that leprosy should be taken into consideration by practitioners when making diagnoses in countries with low incidence rates. If leprosy remains unrecognised, the lack of timely treatment can lead to permanent consequences for the patients. It is therefore noteworthy that the WHO Global Leprosy Strategy 2016--2020 includes monitoring strategies for industrialised countries.

The world has the medicine and knowledge to treat and prevent leprosy and yet the disease persists. What are the reasons for this persistence? One of the possible causes might be related to the long history of discrimination of people who have leprosy. The third pillar of the WHO Global Leprosy Strategy 2016--2020 is to stop discrimination and promote inclusion. Although WHO provides free multidrug therapy in high-incidence areas, beyond the clinical aspect, leprosy remains a stigmatising social problem that is difficult to eradicate. Leprosy-related fear leads to discrimination and marginalisation of those who are affected, often preventing them from seeking proper diagnosis and treatment. According to WHO, 13 countries, mainly Asian and among them India, Thailand, and Singapore, still have legislations allowing discrimination based on leprosy. Forms of discrimination vary and can be related to segregation, employment, immigration, and even the right to vote or use public transport. Just four years ago, Nicaragua changed their law, entitling patients with leprosy to receive assistance in hospitals without being segregated. Only this year, in 2019, India changed their legislation so that leprosy is not considered grounds for divorce. In Sri Lanka, laws are still in place to allow discrimination and segregation of the affected.

2020 is approaching and a leprosy-free world seems an improbable target in such a short time. In largely affected countries, early detection campaigns are needed, together with efforts to increase awareness among the population and fight the disease both on a clinical and social level. The WHO initiative to boost the reduction in cases thanks to single-dose rifampicin chemoprophylaxis shows great potential. For this to happen, it should be made available as soon as possible in areas at high risk, with the global support to cover its additional costs. Another matter that was not mentioned in the WHO Global Leprosy Strategy 2016--2020, but that deserves attention, is disability care and management of those affected. Currently, there is no programme in place to take care of patients with disabilities and their families. This remains an underdiscussed global health issue that should be considered to guarantee proper clinical support for affected patients.

Unfortunately, as *The Herald* article reminds us, Hansen\'s disease is still a reality for many countries. Leprosy might be eradicated, but it is certainly not yet eliminated, and it is now time to intensify global efforts to fight this disease and its stigma worldwide once and for all.
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